The findings suggest that targeting Mlkl or Ripk3 could provide therapeutic benefits in reducing age-related liver inflammation and pathology; however, Mlkl is a better candidate based on the adverse effects of Ripk3 deletion on glucose intolerance and lifespan. Here, MLKL is linked to Glucose intolerance.